Beyondspring Inc
NASDAQ:BYSI
Intrinsic Value
BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. [ Read More ]
The intrinsic value of one BYSI stock under the Base Case scenario is 0.57 USD. Compared to the current market price of 2.41 USD, Beyondspring Inc is Overvalued by 76%.
Valuation Backtest
Beyondspring Inc
Run backtest to discover the historical profit from buying and selling BYSI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Beyondspring Inc
Current Assets | 25.8m |
Cash & Short-Term Investments | 15.4m |
Other Current Assets | 10.4m |
Non-Current Assets | 7.1m |
PP&E | 6.7m |
Other Non-Current Assets | 341k |
Current Liabilities | 6.8m |
Accounts Payable | 1.5m |
Accrued Liabilities | 2.5m |
Other Current Liabilities | 2.9m |
Non-Current Liabilities | 44.1m |
Other Non-Current Liabilities | 44.1m |
Earnings Waterfall
Beyondspring Inc
Revenue
|
2.2m
USD
|
Operating Expenses
|
-52.9m
USD
|
Operating Income
|
-50.7m
USD
|
Other Expenses
|
4.7m
USD
|
Net Income
|
-46m
USD
|
Free Cash Flow Analysis
Beyondspring Inc
BYSI Profitability Score
Profitability Due Diligence
Beyondspring Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Beyondspring Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
BYSI Solvency Score
Solvency Due Diligence
Beyondspring Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Beyondspring Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BYSI Price Targets Summary
Beyondspring Inc
According to Wall Street analysts, the average 1-year price target for BYSI is 1.25 USD .
Shareholder Return
BYSI Price
Beyondspring Inc
Average Annual Return | -33.58% |
Standard Deviation of Annual Returns | 35.45% |
Max Drawdown | -98% |
Market Capitalization | 94m USD |
Shares Outstanding | 39 015 500 |
Percentage of Shares Shorted | 9.98% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The company is headquartered in New York City, New York and currently employs 103 full-time employees. The company went IPO on 2017-03-09. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).
Contact
IPO
Employees
Officers
The intrinsic value of one BYSI stock under the Base Case scenario is 0.57 USD.
Compared to the current market price of 2.41 USD, Beyondspring Inc is Overvalued by 76%.